Biohaven Shares Rise After FDA Accepts Vyglxia Resubmission for Review

Biohaven's shares increased following the FDA's acceptance of its resubmitted New Drug Application for Vyglxia (troriluzole) to treat spinocerebellar ataxia. This resubmission comes after a Complete Response Letter was issued in November 2025. The FDA has scheduled a target decision date for the first quarter of 2027 and will hold an advisory committee meeting during the review process.